Alnylam Pharmaceuticals (ALNY Quick QuoteALNY - Free Report) reported $1.29 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 66.9%. EPS of $1.84 for the same period compares to $0.32 a year ago.

The reported revenue represents a surprise of -2.09% over the Zacks Consensus Estimate of $1.32 billion. With the consensus EPS estimate being $2.05, the EPS surprise was -10.24%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Product revenues, net: $1.17 billion versus the seven-analyst average estimate of $1.21 billion. The reported number represents a year-over-year change of +74.4%.
• Revenues- Net revenues from collaborations: $47.17 million versus the five-analyst average estimate of $51.11 million. The reported number represents a year-over-year change of -23.3%.
• Revenues- Royalty revenue: $71.67 million versus $56.25 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +79.3% change.
• Net Product Revenue - Total TTR: $1.03 billion versus the four-analyst average estimate of $1.08 billion.
• Net Product Revenue- Oxlumo: $52.12 million compared to the $53.69 million average estimate based on four analysts. The reported number represents a change of +11.2% year over year.
• Net Product Revenue- Givlaari: $89.76 million versus the four-analyst average estimate of $82.64 million. The reported number represents a year-over-year change of +11%.
• Net Product Revenue - Total Rare: $141.89 million versus $138.3 million estimated by four analysts on average.
• Net Product Revenue- Onpattro: $18.46 million versus the three-analyst average estimate of $24.19 million. The reported number represents a year-over-year change of -64.7%.
• Net Product Revenue- Amvuttra: $1.01 billion versus the three-analyst average estimate of $1.05 billion. The reported number represents a year-over-year change of +105.7%.

View all Key Company Metrics for Alnylam here>>>

Shares of Alnylam have returned -5% over the past month versus the Zacks S&P 500 composite's -1.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.